{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:56:08Z","timestamp":1790664968015,"version":"4.1.0"},"reference-count":24,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"<jats:p>India\u2019s approval of TAK-003 (Qdenga) on July 20, 2026, marks a defining moment in dengue prevention, yet four-serotype complexity demands a calibrated rather than uniform strategy. Built on a live-attenuated DENV-2 backbone, TAK-003 generates lower type-specific neutralising antibody titres \u2014 most critically against DENV-3 \u2014 an imbalance compounded by original antigenic sin, which may further limit cellular priming against DENV-3 and DENV-4. India\u2019s epidemiology amplifies these concerns: DENV-3 accounted for nearly 80% of typed cases in Bengaluru in 2024 \u2014 a regional signal, though serotype dominance varies across States \u2014 and large seronegative peri-urban populations remain vulnerable. NIH TV003-derived vaccines, including India\u2019s DengiAll in Phase 3, incorporate attenuated strains of all four serotypes, offering potentially broader immunity. TAK-003\u2019s demonstrated efficacy against severe dengue and hospitalisation \u2014 including in seronegative participants \u2014 makes it a valuable first-line tool. We argue for a phased, serotype-informed strategy: deploy TAK-003 now, while building surveillance capacity for vaccines with potentially broader serotype coverage.<\/jats:p>","DOI":"10.25259\/ijmr_1987_2026","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:25:12Z","timestamp":1789197912000},"page":"535-541","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dengue vaccines and serotype complexity: Why India needs a calibrated strategy"],"prefix":"10.25259","volume":"164","author":[{"given":"Vipin M.","family":"Vashishtha","sequence":"first","affiliation":[{"name":"Department of Paediatrics, Mangla Hospital Research Centre, Bijnor, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Kumar Child Clinic, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"10.25259\/IJMR_1987_2026\/ref-2","doi-asserted-by":"publisher","first-page":"e1065","DOI":"10.1016\/S2214-109X(19)30250-5","article-title":"Burden of dengue infection in India, 2017: A cross-sectional population based serosurvey","volume":"7","author":"Murhekar","year":"2019","journal-title":"Lancet Glob Health."},{"key":"10.25259\/IJMR_1987_2026\/ref-4","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob Health."},{"key":"10.25259\/IJMR_1987_2026\/ref-5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science."},{"key":"10.25259\/IJMR_1987_2026\/ref-6","first-page":"572","article-title":"On the doctrine of original antigenic sin","volume":"104","author":"Francis","year":"1960","journal-title":"Proc Am Philos Soc."},{"key":"10.25259\/IJMR_1987_2026\/ref-7","doi-asserted-by":"publisher","first-page":"636","DOI":"10.4269\/ajtmh.24-0416","article-title":"Prevalence of different dengue serotypes in northern India, 2021-2022: A tertiary care hospital-based study","volume":"112","author":"Dinkar","year":"2024","journal-title":"Am J Trop Med Hyg."},{"key":"10.25259\/IJMR_1987_2026\/ref-8","doi-asserted-by":"publisher","first-page":"e0013636","DOI":"10.1371\/journal.pntd.0013636","article-title":"Dengue transmission dynamics in an urban setting in western India","volume":"20","author":"Balasubramani","year":"2026","journal-title":"PLoS Negl Trop Dis."},{"key":"10.25259\/IJMR_1987_2026\/ref-9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/trstmh\/trag006","article-title":"Molecular characterization of circulating dengue virus serotypes and genotypes from central India","volume":"120","author":"Katiyar","year":"2026","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"10.25259\/IJMR_1987_2026\/ref-10","doi-asserted-by":"publisher","first-page":"100485","DOI":"10.1016\/j.lansea.2024.100485","article-title":"Evolving dengue serotype distribution with dominance of dengue virus- 3 in Bangalore: Critical insights for vaccine efficacy and implementation","volume":"30","author":"Uppoor","year":"2024","journal-title":"Lancet Reg Health Southeast Asia."},{"key":"10.25259\/IJMR_1987_2026\/ref-11","doi-asserted-by":"publisher","first-page":"e0013883","DOI":"10.1371\/journal.pntd.0013883","article-title":"Tracking the clinico-microbiological profile and molecular characterization of dengue cases during the monsoon-season in Belagavi, Karnataka","volume":"20","author":"Patil","year":"2026","journal-title":"PLoS Negl Trop Dis."},{"key":"10.25259\/IJMR_1987_2026\/ref-12","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1038\/s41591-025-03771-y","article-title":"Efficacy, public health impact and optimal use of the Takeda dengue vaccine","volume":"31","author":"Cracknell Daniels","year":"2025","journal-title":"Nat Med."},{"key":"10.25259\/IJMR_1987_2026\/ref-13","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_1987_2026\/ref-14","doi-asserted-by":"publisher","first-page":"e0009258","DOI":"10.1371\/journal.pntd.0009258","article-title":"Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)","volume":"15","author":"White","year":"2021","journal-title":"PLoS Negl Trop Dis."},{"key":"10.25259\/IJMR_1987_2026\/ref-15","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3389\/fimmu.2019.02125","article-title":"Human T cell response to dengue virus infection","volume":"10","author":"Tian","year":"2019","journal-title":"Front Immunol."},{"key":"10.25259\/IJMR_1987_2026\/ref-16","doi-asserted-by":"publisher","first-page":"E2046","DOI":"10.1073\/pnas.1305227110","article-title":"Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells","volume":"110","author":"Weiskopf","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.25259\/IJMR_1987_2026\/ref-17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1128\/JVI.02129-14","article-title":"The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes","volume":"89","author":"Weiskopf","year":"2015","journal-title":"J Virol."},{"key":"10.25259\/IJMR_1987_2026\/ref-18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41541-024-00967-0","article-title":"Long term T cell response and safety of a tetravalent dengue vaccine in healthy children","volume":"9","author":"Mandaric","year":"2024","journal-title":"NPJ Vaccines."},{"key":"10.25259\/IJMR_1987_2026\/ref-19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J Infect Dis."},{"key":"10.25259\/IJMR_1987_2026\/ref-20","doi-asserted-by":"publisher","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci Transl Med."},{"key":"10.25259\/IJMR_1987_2026\/ref-21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, attenuated, tetravalent butantan-dengue vaccine in children and adults","volume":"390","author":"Kall\u00e1s","year":"2024","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_1987_2026\/ref-22","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/s41591-026-04255-3","article-title":"Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine","volume":"32","author":"Kall\u00e1s","year":"2026","journal-title":"Nat Med."},{"key":"10.25259\/IJMR_1987_2026\/ref-25","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet."},{"key":"10.25259\/IJMR_1987_2026\/ref-26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_1987_2026\/ref-27","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and Long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_1987_2026\/ref-28","first-page":"203","article-title":"WHO position paper on dengue vaccines \u2013 May 2024","volume":"99","author":"World Health Organization","year":"2024","journal-title":"Wkly Epidemiol Rec."}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/dengue-vaccines-and-serotype-complexity-why-india-needs-a-calibrated-strategy\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/dengue-vaccines-and-serotype-complexity-why-india-needs-a-calibrated-strategy\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:58:15Z","timestamp":1790661495000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/dengue-vaccines-and-serotype-complexity-why-india-needs-a-calibrated-strategy\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":24,"alternative-id":["10.25259\/IJMR_1987_2026"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_1987_2026","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"535"}}